Last reviewed · How we verify
NCT06037759: CBKD
Novel Cardiovascular Biomarkers in Patients With Kidney Disease
trial testing Cardiac Biomarkers in Haemodialysis Complication in 100 participants. Not yet recruiting.
1 November 2025
Quick facts
| Lead sponsor | Liverpool University Hospitals NHS Foundation Trust |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 November 2023 |
| Primary completion | 1 November 2025 |
| Estimated completion | 1 November 2026 |
Drugs / interventions tested
- Cardiac Biomarkers
- Lipidomics
- Proteomics
Conditions studied
- Haemodialysis Complication — all drugs for Haemodialysis Complication →
- Major Adverse Cardiac Events — all drugs for Major Adverse Cardiac Events →
Sponsor
Liverpool University Hospitals NHS Foundation Trust
Who can join
18 and older, any sex, with Haemodialysis Complication or Major Adverse Cardiac Events. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic kidney disease (CKD) is a long-term condition where the kidneys do not work as well as they should. End-stage kidney failure (ESKD) is the final, irreparable stage of chronic kidney disease (CKD), where kidney function has worsened, so the kidneys can no longer function independently. At this stage, dialysis is required to remove waste products and excess fluid from the blood. There are two types of dialysis. In haemodialysis (HD), blood is pumped out of the body to an artificial kidney machine and returned to the body by tubes that connect a person to the machine. In peritoneal dialysis (PD), the inside lining of the belly acts as a natural filter. PD has the advantage of being gentler on the heart. HD causes significant stress to the heart by reducing the blood flow to the heart muscle, resulting in heart failure, irregular rhythms, and eventually sudden heart death. A large observational study showed that HD patients had 48% worse survival in the first two years than PD patients. Several molecules ('biomarkers') can be detected in blood and inform doctors of heart damage. Studying the form and function of proteins (Proteomics), including how they work and interact with each other inside cells in patients, could help identify the onset of heart problems. HD patients are also prone to body fat changes (cholesterol/lipids). Due to high cholesterol, there is build-up on the walls of arteries, causing their hardening. In HD patients, this process is faster due to abnormalities in lipid structure. Therefore, studying the heart biomarkers, protein, and lipid makeup of HD patients may help to find people at substantial risk of heart and vascular problems and if they are likely to become unwell due to these heart problems.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06037759
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Haemodialysis Complication
Currently open trials in the same condition.
- NCT03004547 — Sodium Deposition in Soft Tissues of Patients with Kidney Disease · recruiting
Other Liverpool University Hospitals NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07391553 — Achilles Tendon Rupture Patient Outcomes at 12 Months · not yet recruiting
- NCT07034469 — Air Tamponade Versus Fluorinated Gas Tamponade for Rhegmatogenous Retinal Detachment · NA · not yet recruiting
- NCT06566638 — Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction o · NA · not yet recruiting
- NCT06600620 — Intelligent Monitoring to Predict Atrial Fibrillation · suspended
- NCT06271031 — Process Mapping and Data Collection to Inform a Computer Simulation Model of Hospitalised Patients With Bloodstream Infe · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06037759 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liverpool University Hospitals NHS Foundation Trust
- Last refreshed: 18 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06037759.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing